Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Certepetide,Panitumumab,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Haystack Oncology and Lisata Therapeutics Start Collaboration to Use MRD™ Tech
Details : Through the collaboration, Lisata will utilize MRD technology to detect ctDNA in a clinical trial evaluating CEND-1 (certepetide) combined with chemotherapy for the treatment of pancreatic cancer.
Brand Name : CEND-1
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 18, 2024
Lead Product(s) : Certepetide,Panitumumab,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Certepetide,Panitumumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lisata Completes Enrollment for CENDIFOX Pancreatic Trial
Details : LSTA1 (certepetide) is an integrin alpha-V antagonist which is being evaluated in combination with folfirinox-based therapies for pancreatic, colon, and appendiceal cancers.
Brand Name : LSTA1
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 13, 2024
Lead Product(s) : Certepetide,Panitumumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sotorasib,Panitumumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data showed that combining LUMAKRAS®/LUMYKRAS® (sotorasib) with Vectibix® (panitumumab), Amgen's monoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody, demonstrated encouraging efficacy and safety.
Brand Name : Lumakras
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 12, 2022
Lead Product(s) : Sotorasib,Panitumumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Panitumumab,Calcium Folinate,Fluorouracil
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results of trial showed that mFOLFOX6 + Vectibix (Panitumumab) combination provides a statistically significant improvement in OS over mFOLFOX6 + bevacizumab combination in patients with a left-sided primary tumor or regardless of tumor locations.
Brand Name : Vectibix
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 05, 2022
Lead Product(s) : Panitumumab,Calcium Folinate,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sotorasib,Panitumumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : New data support initiation of Phase 3 trial of LUMAKRAS plus Vectibix in patients with 3L+ KRAS G12C-mutated advanced colorectal cancer (CRC). 9.7% response rate observed with LUMAKRAS monotherapy and highlight the importance of combination therapy in C...
Brand Name : Lumakras
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2021
Lead Product(s) : Sotorasib,Panitumumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?